CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

• DOI: 10.1056/evidoa2300213
• Publication Date: 2024-03-26T13:30:22Z
• Authors: Guido Ghilardi; Staci Williamson; Raymone Pajarillo; Luca Paruzzo; Linhui Chen; Connor Grady; Abigail Doucette; Eneida Nemecek; Giulia Gabrielli; Stefan K. Barta; Jakub Svoboda; Elise A. Chong; Rebecca Yelton; Sunita D. Nasta; Daniel J. Landsburg; Ositadimma Ugwuanyi; Andy I. Chen; Levanto Schachter; Griffin White; Hatcher J. Ballard; Elizabeth Weber; Cara Curley; David L. Porter; Alfred L. Garfall; Wei-Ting Hwang; Carmen E. Guerra; Richard T. Maziarz; Stephen J. Schuster; Marco Ruella
• Keywords: Male; Adult; Receptors, Chimeric Antigen; Antigens, CD19; Humans; Female; Middle Aged; Immunotherapy, Adoptive; Minority Groups; Aged

BackgroundAdministration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care centers. We investigated whether minority health populations (MHPs) have equal CART19 their outcomes are similar those non-MHPs. MethodsWe analyzed the prevalence clinical patients treated with commercial at two geographically socioeconomically different institutions: Abramson Cancer Center (ACC, Philadelphia, Pennsylvania) Knight Institute (KCI, Portland, Oregon). ResultsIn ACC catchment area, 8956 were diagnosed NHL between 2015 2019 (latest available data from state registry), including 17.9% MHPs. In ACC, 2018 2022 (CART became in 2018), 1492 LBCL treated, 194 received CART19. The proportion MHPs was 15.7% entire cohort but only 6.7% cohort. During same time, KCI 4568 NHL, 4.2% KCI, 396 47 6.6% 3-month response, survival, toxicities after infusion showed results, although number who limited. ConclusionsThis study shows that centers preserved appeared reduced immunotherapy. Although seemed non-MHPs, small sample size precludes drawing firm conclusions. Further studies needed. (Funded by Laffey McHugh Foundation others.)